Skip to content
MARKETS / NASDAQ / WHWK
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Whitehawk Therapeutics, Inc. WHWK

18 fiscal years on record · USD · FY2025 reported · SEC filings only
$7.1M
▼ 72.5% YoY
$-20.6M
$-98.0M
In brief

What this company does

We are a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology that are intended to efficiently deliver improved cancer treatments. In December 2024, we entered into an intellectual property license agreement (the “WuXi License Agreement”) with WuXi Biologics (Shanghai FX) Co., Ltd. (“WuXi Biologics”) for the development and global commercialization of a portfolio of three next generation antibody drug conjugates (“ADCs”) targeting clinically validated, broadly overexpressed tumor antigens in high potential cancer indications with significant unmet need. We were originally incorporated in the State of Delaware in November 2007 under the name “Zeta Acquisition Corp. II.” On March 18, 2025, in connection with such transaction, we changed our name from "Aadi Bioscience, Inc." to "Whitehawk Therapeutics, Inc." As of December 31, 2025, we had 23 full-time or part-time employees.

Written from the business description in Whitehawk Therapeutics, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 12 March 2026. Every sentence was checked against that document before publication.

Growth
USD 7.1M
Revenue, FY2025 · full 18-year series below
Revenue $M Net income $M
FY2025 · Revenue 7.1 · Net income -20.6
10M20M-40M-80M2008201120142017202020232025
Compound annual growth
−22.3%
−12.6%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −12.6% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−288 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -1601.1% · Net -288.3%
-500%-1000%-1500%2008201120142017202020232025
ROE
FY2025 · ROE -21.8%
-1000%-2000%2008201120142017202020232025

Each USD of equity lost 22 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -98.0
-40M-80M2008201120142017202020232025
Net buybacks $M Dividends $M
FY2022 · Dividends 0.0 · Net buybacks —
2M4M20212022

Total assetsUSD 150.8M
EquityUSD 136.3M
CashUSD 37.6M
Current ratio10.26×

Equity funds 90% of total assets.

The 18-year record
18 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020201920182017201620152014201320122011201020092008
Revenue $B0.00.00.00.00.00.00.00.0··········
Operating income $B−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0··
EBITDA $B−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0········
Income tax $B0.00.00.00.00.00.0············
Net income $B−0.0−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0········
EPS, diluted $−0.33−2.36−2.44−2.69−12.41−1.76−0.57−0.31−1.03−24.52−0.01−0.01−0.01−0.01−0.010.00··
Dividend / sh $··················
Payout %···−0−4·············
ROE %−21.8−80.8−49.9−41.1−177.6·−93.9−27.3·········−2401.6
Shares out B0.050.020.020.020.020.000.040.040.030.000.010.010.010.010.010.01··

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 1 failures in 57 reconciliationsAUDITED

Reconciled in 17 of 19 fiscal years. 33 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente1 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2008

Share this section

Download image